In the News
Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII
Tramiprosate, like so many others, could have been consigned to the scrap heap of once-promising AD meds that didn’t quite make the grade, never to be [...]
Alzheon Highlighted as One of the “Top 20 Life Science Startups to Watch in the U.S.”
Alzheon is focused on developing treatments for patients with Alzheimer’s disease and other neurological and psychiatric disorders. The company’s lead clinical product candidate, ALZ-801, is an [...]
Alzheon Gets $10M to Take Castoff Alzheimer’s Drug Into Pivotal Test
Run by a veteran of drug R&D for Alzheimer’s disease, Alzheon is betting that a smart trial design and a little chemistry work could [...]
Alzheimer’s startup Alzheon bags $10M and beats a path to Phase III
The veteran Alzheimer's researchers at Alzheon believe their novel treatment for the disease has a chance to come through where so many others have failed. Alzheon's [...]
Lexington’s Alzheon gives its own Alzheimer’s news to rival Biogen’s
While it’s the biggest, Biogen is not the only Bay State biotech presenting promising data for an Alzheimer’s drug this morning. The small Lexington-based biotech, Alzheon, [...]
Six drugs that could change the world
The strength of the state’s world-class drug developers is usually measured in terms of jobs and economics, rather than the effect on human health in coming [...]
Startup Finds Hope in Second Look at “Failed” Alzheimer’s Drugs
Alzheon will first take a closer look at a drug designed to target the brain-damaging amyloid plaques that are the hallmarks of Alzheimer’s. In the hands [...]
Alzheimer’s team tackles a daunting R&D field with a new game plan
The drug is tramiprosate, which flunked a big study back in 2009. It's been rebuilt, so to speak, so it can be delivered through the gut [...]